Aptevo Therapeuticsの空売り状況は、投資家がAptevo Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Aptevo Therapeutics (NASDAQ:APVO) 株価情報, 空売り情報

Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics Inc

Wells Fargo analyst Elyse Greenspan maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Overweight and lowers the price target from $264 to $246.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Reinsurance Gr, Lowers Price Target to $246

Wells Fargo analyst Elyse Greenspan maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and lowers the price target from $118 to $108.

Wells Fargo Maintains Equal-Weight on Prudential Financial, Lowers Price Target to $108

Wells Fargo analyst Elyse Greenspan maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Underweight and lowers the price target from $74 to $68.

Wells Fargo Maintains Underweight on Principal Financial Group, Lowers Price Target to $68

Wells Fargo analyst Elyse Greenspan maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and lowers the price target from $97 to $91.

Wells Fargo Maintains Overweight on MetLife, Lowers Price Target to $91

Wells Fargo analyst Elyse Greenspan maintains Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) with a Equal-Weight and lowers the price target from $36 to $31.

Wells Fargo Maintains Equal-Weight on Lincoln National, Lowers Price Target to $31

Wells Fargo analyst Elyse Greenspan maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Overweight and lowers the price target from $141 to $140.

Wells Fargo Maintains Overweight on Globe Life, Lowers Price Target to $140

Wells Fargo analyst Elyse Greenspan maintains Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) with a Overweight and lowers the price target from $62 to $59.

Wells Fargo Maintains Overweight on Equitable Holdings, Lowers Price Target to $59

Wells Fargo analyst Elyse Greenspan maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Overweight and lowers the price target from $38 to $35.

CRBG

Wells Fargo Maintains Overweight on Corebridge Financial, Lowers Price Target to $35

Wells Fargo analyst Elyse Greenspan maintains Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) with a Equal-Weight and lowers the price target from $59 to $52.

Brighthouse Financial, Inc. - Common Stock

Wells Fargo Maintains Equal-Weight on Brighthouse Finl, Lowers Price Target to $52

Wells Fargo analyst Elyse Greenspan maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Underweight and raises the price target from $33 to $34.

BWIN

Wells Fargo Maintains Underweight on Baldwin Insurance, Raises Price Target to $34

Wells Fargo analyst Elyse Greenspan maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Equal-Weight and lowers the price target from $69 to $66.

RYAN

Wells Fargo Maintains Equal-Weight on Ryan Specialty Hldgs, Lowers Price Target to $66

Wells Fargo analyst Elyse Greenspan maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $223 to $232.

Wells Fargo Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $232

WIIM

AAPL

AKAM

APPS

ASML

CDNS

CMTL

COHR

CSAI

DATS

DELL

ENPH

ENTG

FSLY

GDDY

GOOG

GOOGL

INTC

iShares Dow Jones US Technology Sector Index Fund

LAES

LDTC

LITE

LMFA

MASS

MPWR

MRVL

MSFT

NTNX

NVDA

OKTA

OLED

OUST

PCOR

Penguin Solutions, Inc. - Ordinary Shares

PENG

PLTR

PRSO

QCOC

RDZN

SAIL

SEDG

SHOP

SNCR

SNOW

SNPS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

STAI

ZETA

Shares of technology stocks are trading lower amid an overall market reversal following Wednesday's surge.

In the span of a single week, two countries issued sweeping <a href="https://www.benzinga.com/cannabis">cannabis</a> decrees, one opening a cautious path forward, the other slamming the door shut. Panama clarified its medical cannabis law with updated regulations, expanding access under strict conditions. Italy, meanwhile, stunned its own industry by banning the sale, possession and production of all hemp flowers, including CBD, through an emergency decree.
The contrast between the two reveals a widening global divide on cannabis policy between regulated progress and reactive prohibition, between evidence-based reform and political impulse.
<h3 class="wp-block-heading">Panama: Regulating Cannabis With Guardrails</h3>
On April 4, Panama published Decree No. 6 in its official gazette, refining the country's framework for the therapeutic use of cannabis. The regulation replaces a 2022 decree and aims to clarify the implementation of Law 242, which legalized medical cannabis in 2021. As <a href="https://elplanteo.com/cannabis-medicinal-panama-nueva-regulacion/">El Planteo reported</a>, the new rules address everything from physician prescribing rights to where cannabis can be consumed.
Patients may now obtain prescriptions from any licensed physician, mirroring the prescription model used for opioids. The law also outlines limitations: no use in public or workplaces (unless approved), a ban on use by people in high-risk professions and a prohibition on mixing cannabis with alcohol or other substances.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/04/44745709/from-malbec-to-marijuana-argentinas-provincial-push-fuels-cannabis-tourism-science-and-policy">From Malbec To Marijuana: Argentina&#8217;s Provincial Push Fuels Cannabis Tourism, Science And Policy</a>
Crucially — and controversially — vaporizers are banned, despite their widespread use in medical cannabis globally. "The Supreme Court had already declared a prohibition on vaping unconstitutional, and here they repeat it twice in the same article," said <a href="https://elplanteo.com/carlos-goma-ossa-cannabis-panama/">Carlos Ossa</a>, a key figure in Panama's cannabis reform movement. "Worldwide, 70% of patients use vaporizers. In Panama, we're banning the most common method. It makes no sense."
While the decree does not enable adult-use cannabis, it does preserve pathways for medical access and seeks to bring consistency to the regulatory landscape. However, production licenses remain pending and Panama continues to rely entirely on imported products, raising costs and delaying access.
Advocates argue that there's a need to move faster. Without domestic cultivation or manufacturing, Panama's cannabis industry —and its patients— remain tethered to expensive supply chains and slow bureaucratic processes.
<h3 class="wp-block-heading">Italy: From Legal Gray Zone To Full Prohibition</h3>
In stark contrast, Italy's government issued a decree banning all hemp flowers and CBD products—even those with negligible or non-psychoactive THC content. The surprise decision, issued on a Friday night under emergency powers, prohibits the cultivation, processing, sale and possession of cannabis sativa flowers, as El Planteo reported <a class="" href="https://elplanteo.com/italia-prohibe-todas-las-flores-de-canamo-y-cbd-sin-filtros-sin-dialogo-sin-ciencia/">here</a>.
The move affects industrial hemp, CBD wellness products, cosmetics, teas and even pet supplements, effectively wiping out a sector that had operated—often in legal limbo— under EU guidelines protecting hemp products with less than 0.3% THC.
Italy's decision comes via Article 77 of the Constitution, which allows decree-laws in cases of urgency. But critics argue the government, led by Prime Minister Giorgia Meloni, bypassed consultation with stakeholders and ignored both EU legal precedent and national court rulings that recognized the legality of hemp-derived CBD.
According to Canapa Sativa Italia, the ban jeopardizes 22,000–30,000 jobs. It also endangers over 3,000 businesses, many of which have invested heavily in licensed operations, infrastructure and R&amp;D. Industry groups warn of economic disaster and legal chaos.
"This measure destroys a well-established economic and social reality," advocates from Canapa Sativa Italia stated. "It nullifies millions in investment and throws thousands of people into legal uncertainty."
EU courts have previously ruled that CBD is not a narcotic and that its commerce cannot be restricted without clear scientific justification. Italy's decree ignores that position, risking potential conflict with European trade law and triggering a wave of legal challenges.
<h3 class="wp-block-heading">Diverging Paths, Global Questions</h3>
Panama and Italy both issued cannabis-related decrees last week, but their political contexts, legal justifications and industry implications are very different.
Panama's approach is cautious but constructive, offering physicians broader prescribing rights and reinforcing the legitimacy of medical cannabis, even while imposing restrictions and lagging on production.
Italy's decree, by contrast, reflects a hardline shift toward prohibition, one that defies both legal precedent and economic rationale—prioritizing security rhetoric over patient rights, economic stability and EU law.
Taken together, these cases illustrate a deepening global split over cannabis policy: between science and ideology, regulation and regression, dialogue and decree.
As countries continue to update their cannabis laws, the choices made in places like Panama and Italy will shape not only national markets but also the international perception of cannabis as a legal, medical, and economic force.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/04/44743798/chile-moves-to-legalize-adult-use-cannabis-with-backing-from-presidential-candidate">Chile Moves To Legalize Adult-Use Cannabis With Backing From Presidential Candidate</a></li>
</ul>
Photo: Shutterstock

Cannabis

Latin America

Eurozone

Politics

One Step Forward, One Step Back: Panama Regulates Cannabis, Italy Bans It

Wells Fargo analyst Elyse Greenspan maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Overweight and raises the price target from $370 to $372.

Wells Fargo Maintains Overweight on Arthur J. Gallagher, Raises Price Target to $372

Wells Fargo analyst Elyse Greenspan maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Overweight and lowers the price target from $126 to $125.

Wells Fargo Maintains Overweight on The Hartford Insurance Gr, Lowers Price Target to $125

BofA Securities analyst Justin Post noted Thursday that President Donald Trump announced a 90-day pause on reciprocal tariffs, keeping the 10% baseline in place. Per Trump, the pause comes after 75-plus countries called U.S. officials to negotiate trade agreements, even as he hiked tariffs on Chinese imports to 125% in response to China's 84% rate on U.S. goods.
The Nasdaq jumped over 12% as investors recalibrated tariff and recession fears. Talks are underway with key Asian partners like Vietnam (tariff at 46%), Japan (24%) and India (26%), with Treasury Secretary Scott Bessent set to meet them soon, per Bloomberg. While China tariffs remain a risk, broader negotiations could help online retailers stabilize supply chains.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44718635/amazon-faces-tariff-turbulence-but-analyst-sees-favorable-trends" rel="noreferrer noopener">Amazon Faces Tariff Turbulence But Analyst Sees Favorable Trends</a>
In the case where the Street can anticipate a resolution to all tariff issues over the next 12-18 months, Post noted the most significant opportunity for more discretionary names in his e-commerce coverage group — ACV Auctions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>), Wayfair Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) — that have been hardest hit over the past three weeks.
Amazon&#8217;s retail does have significant exposure to China (China sellers could be over 30% of third-party sellers), but pauses on tariffs in other countries will allow for product substitution. Key questions for first-quarter earnings and second-quarter outlooks will be to what degree consumers have pulled forward spending ahead of expected tariffs, and how much of a pass Street will give companies on second-quarter guidance.
As advertising spending is cyclical and depends, in part, on business confidence, Post expects some weakness in second-quarter brand advertising.
Post noted that the announced tariff pause could help soften the potential impact in the second quarter and drive some upside to his recently revised estimates, benefiting the entire sector.
Online media companies, including Pinterest Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), and Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), which have less robust ad auctions and/or higher brand exposure, likely have the most to gain from an improving macro outlook.
Of the three, Post preferred Pinterest for a reduction in tariffs, given its exposure to home goods and fashion with favorable risk/reward. He noted that the group — including Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) — was up between 10% and 25% initially on the tariff pause news, but the stocks remain well below Feb. 14 levels.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672618/trump-tariffs-to-hurt-nike-under-armour-vf-are-ralph-lauren-foot-locker-safer-bets" target="_blank" rel="noreferrer noopener">Trump Tariffs To Hurt Nike, Under Armour, VF: Are Ralph Lauren, Foot Locker Safer Bets?</a></li>
</ul>
Photo: Shutterstock

Social Media

Trading Ideas

ACVA

AMZN

PINS

RDDT

SNAP

Amazon, Wayfair, Pinterest Win Analyst Backing Due To Tariff Pause, Supply Chain Relief, Discretionary Spend Recovery

Wells Fargo analyst Elyse Greenspan maintains Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) with a Overweight and lowers the price target from $23 to $22.

Wells Fargo Maintains Overweight on Hamilton Insurance Group, Lowers Price Target to $22

Editor's Note: This article has been updated to reflect that the fund formerly known as the Invesco Defensive Equity ETF is now the Invesco Bloomberg Pricing Power ETF.
The S&amp;P 500's fireworks this week may have lit up Wall Street, <a href="https://www.benzinga.com/topic/jeremy-siegel">but Jeremy Siegel</a> isn't buying into the revelry just yet.
<h1 class="wp-block-heading">Pause Doesn&#8217;t Equal Peace: Trump's Tariff Timeout Isn't The Endgame</h1>
Despite a 9.5% one-day rally that put the index in rarefied post-World War II territory, Siegel <a href="https://www.cnbc.com/2025/04/10/jeremy-siegel-says-stocks-are-not-out-of-the-woods-yet-due-to-difficult-china-negotiations-ahead.html">told</a> CNBC's Squawk Box that investors celebrating a tariff truce may be getting ahead of themselves. "We're not out of the woods," the WisdomTree chief economist warned, pointing to the looming uncertainty in U.S.-China trade negotiations.
President Donald Trump's 90-day pause on reciprocal tariffs sparked the market&#8217;s surge, but with the 10% tariff now permanent and China countering with 84% on U.S. goods, this is hardly a peace treaty. 
According to Siegel, investor sentiment remains shaky, still reeling from the initial tariff shock. That means the S&amp;P 500, down 11% from its highs and still negative for April, may struggle to reclaim its February peak anytime soon.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44730455/bearish-sentiment-hits-7-week-high-mimicking-35-year-old-record-which-marked-the-bottom-of-the-october-1990-bear-market">Bearish Sentiment Hits 7-Week High, Mimicking 35-Year Old Record Which Marked The Bottom Of The October 1990 Bear Market</a>
<h1 class="wp-block-heading">Next Stop: July 9 and More Trade Turbulence</h1>
The market's next inflection point? Likely July 9, when the next tariff round could escalate tensions further.
For investors riding the broader index rebound, ETFs like the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) have all surged — but Siegel suggests caution.
For investors looking to play defense, sector ETFs like the Invesco Bloomberg Pricing Power ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POWA#NYSE">POWA</a>) or the Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) may offer some shelter.
On the flip side, those still leaning into the rebound could watch the iShares U.S. Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>) as tech has led past snapbacks, but remains exposed to global trade flows.
This isn't an "all clear" for risk-on strategies. Bulls may want to wait for more than just headlines before charging back in.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734009/tech-sector-heading-into-a-period-of-mass-uncertainty-amid-tariffs-and-upcoming-earnings-season-says-dan-ives-the-damage-is-real">Tech Sector Entering A Period Of &#8216;Mass Uncertainty&#8217; Amid Tariffs And Upcoming Earnings Season, Says Dan Ives: &#8216;The Damage Is Real&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/zimmytws">zimmytws</a> via Shutterstock

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Economics

ETFs

POWA

TSX:DEF

Jeremy Siegel Sounds The Tariff Alarm: Bulls May Want To Be Cautious (UPDATED)

Piper Sandler analyst Clarke Jeffries maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and lowers the price target from $143 to $113.

FOUR

Piper Sandler Maintains Overweight on Shift4 Payments, Lowers Price Target to $113

Press Releases

Aptevo Therapeutics Announces Exercise of Warrants for  $6.2 Million Gross Proceeds

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo to Participate in March Conferences

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Offerings

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Comments

Aptevo Therapeutics

空売り

Aptevo Therapeutics (NASDAQ:APVO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル